Rigel Phar­ma scores FDA ap­proval for leukemia, kick­ing off show­down with Servi­er in IDH1

When Rigel Phar­ma bought olu­tasi­denib from For­ma Ther­a­peu­tics, it ac­quired a drug that al­ready se­cured a PDU­FA date at the FDA — for Feb­ru­ary 2023. But reg­u­la­tors are ready to give their OK soon­er than that.

The FDA has ap­proved the IDH1 in­hibitor as a treat­ment for adult pa­tients with re­lapsed or re­frac­to­ry acute myeloid leukemia who have a sus­cep­ti­ble IDH-1 (isoc­i­trate de­hy­dro­ge­nase-1) mu­ta­tion as de­tect­ed by an FDA-green­lit test. Rigel will mar­ket it as Re­zlid­hia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER